Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

NCT00767520 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Exemestane + Dasatinib
DRUG: Exemestane + Placebo

Sponsor

Bristol-Myers Squibb